Klassifizierung der zellbasierten
Therapie-Technologie
Es wird deutlich, dass sich die Landschaft des Entwicklungsstandes und des Einsatzes von Zelltherapien
in den kommenden Jahren aufgrund der sehr positiven Wirksamkeitsdaten im
Bereich der Immunzelltherapie erheblich verändern wird.
Somatische Zelltechnologien
Technologien zur Immortalisierung von Zellen
Technologien zur Zellplastizität
Treffen Sie unser Team

Melanie Strauss

René Schweizer

Claudia Luft
Neue Wege für toleranzinduzierende Zelltherapien

Tolerogene Therapie
Die tolerogene Therapie zielt darauf ab, Immuntoleranz zu induzieren, wenn eine pathologische oder unerwünschte Aktivierung der normalen Immunantwort vorliegt.

CAR-T-Zell-Therapie
Chimäre Antigenrezeptor-T-Zellen sind T-Zellen, die gentechnisch so verändert wurden, dass sie einen künstlichen T-Zell-Rezeptor für den Einsatz in der Immuntherapie produzieren.

Gentechnisch veränderte TCR-Therapie
Bei der TCR-Therapie werden T-Zellen genetisch so verändert, dass sie einen neuen Rezeptor produzieren, der sie in die Lage versetzt, sich an bestimmte Zielproteine auf Tumorzellen zu heften.
Neueste Nachrichten und Artikel

Entwicklung zellbasierter Therapien

Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies
A FACTT is pushing the limits, inviting you to come along and join us !
WHY A FACTT ?
The number of patients with autoimmune diseases and recipients of organ or stem-cell transplants is increasing worldwide. Currently, these patients require lifelong administration of immunosuppressive drugs. Often, these drugs are ineffective, expensive and show severe side-effects. More effective and safer therapies aimed at modifying unwanted immune responses permanently or for prolonged periods are needed.
Accumulating knowledge on mechanisms of immune tolerance has led to development of specific Cell-based Tolerance-inducing Therapies (CTT) with the specific objectives to restrain unwanted immune reactions long-term. For patients, personalised CTT will represent a breakthrough for healthcare and quality of life.
Clinical CTT studies are underway or starting in single European institutes. The used CTT products are diverse and the efficacy of therapy is monitored by different parameters. This creates the risk of redundancy in trials and suboptimal performance indicators for comparison of trial outcomes.
The main objective of A FACTT is to initiate a network that will coordinate European CTT efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters. The A FACTT-Action will thus focus and accelerate the CTT field and ensure that the field will progress in an efficient, safe and cost-effective way.
The A FACTT Project
Do you like to quickly learn more about the A FACTT project ? Please click here and find all information about the project, its objectives, its background and the benefits, as well as your starting point to the scientific work being carried out.Read More & Discover A FACTT
How to join A FACTT
Are you interested in the A FACTT project and would you like to join us and become part of Europe’s biggest network on Cell-based Tolerance-inducing Therapies ? Please apply here !Read More & Discover A FACTT
Contact A FACTT